Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12802060 | 0.89 | HDAC1 (0.41) | TP53OPRM1OPRD1OPRK1MGLL | |
| SCHEMBL12802177 | 0.88 | CNR1 (0.38) | OPRM1OPRD1OPRK1MEN1KMT2A | |
| SCHEMBL12802506 | 0.85 | LPL (0.45) | — | |
| SCHEMBL12802091 | 0.83 | TSHR (0.38) | TAAR1 | |
| SCHEMBL9490025 | 0.80 | TP53 (0.52) | TP53MGLLMEN1KMT2ACYP1A2 | |
| SCHEMBL3642896 | 0.80 | DAO (0.42) | OPRM1OPRD1OPRK1MEN1KMT2A | |
| SCHEMBL30076650 | 0.80 | TAAR1 (0.57) | TP53TAAR1IDO1 | |
| SCHEMBL910853 | 0.80 | MGLL (0.41) | TP53MGLLMEN1KMT2ACYP1A2 | |
| SCHEMBL20819294 | 0.80 | PNMT (0.45) | OPRM1OPRD1OPRK1TAAR1 | |
| SCHEMBL27523197 | 0.80 | TP53 (0.39) | TP53MGLLMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545653-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. | 2023-07-04 | — | — | US | disclosed |
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. | 2020-10-22 | — | — | US | disclosed |
| EP-2984055-B1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9758445-B2 | Preparation of surfactants via cross-metathesis | MATERIA, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9663459-B2 | Preparation of surfactants via cross-metathesis | MATERIA, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9587042-B2 | Process for producing modified conjugated diene-based polymer, modified conjugated diene-based polymer, and polymer composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160186094-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160145204-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. | 2016-05-26 | — | — | US | disclosed |
| CN-102731722-B | For the production of the method for modified conjugated diene polymer, modified conjugated diene polymer and polymer composition | SUMITOMO CHEMICAL CO., LTD. (JP) | 2016-03-16 | — | — | CN | disclosed |
| EP-2984055-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | Materia, Inc. (US) | 2016-02-17 | — | — | EP | disclosed |
| WO-2015126462-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-8933165-B2 | Method for producing modified conjugated diene-based polymer, and method for producing polymer composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-13 | — | — | US | disclosed |
| WO-2014169080-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. (US) | 2014-10-16 | — | — | WO | disclosed |
| US-8835564-B2 | Method for producing modified conjugated diene-based polymer, and method for producing polymer composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-16 | — | — | US | disclosed |
| US-20140088242-A1 | METHOD FOR PRODUCING MODIFIED CONJUGATED DIENE-BASED POLYMER, AND METHOD FOR PRODUCING POLYMER COMPOSITION | ZEON CORPORATION (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20140088256-A1 | METHOD FOR PRODUCING MODIFIED CONJUGATED DIENE-BASED POLYMER, AND METHOD FOR PRODUCING POLYMER COMPOSITION | ZEON CORPORATION (JP) | 2014-03-27 | — | — | US | disclosed |
| US-20120252966-A1 | PROCESS FOR PRODUCING MODIFIED CONJUGATED DIENE-BASED POLYMER, MODIFIED CONJUGATED DIENE-BASED POLYMER, AND POLYMER COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545653-B2 | Compound as PPAR agonist and application thereof | PPARA, PPARD, PPARG | TP53 2749/4885OPRM1 608/4885OPRD1 139/4885 |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | PPARA, PPARG, PPARD | TP53 3507/4885OPRM1 758/4885OPRD1 616/4885 |
| US-20160186094-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | SMURF2, EPHX2, SMURF1 | TP53 407/4885OPRM1 4197/4885OPRD1 3346/4885 |
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | PPARA, PPARG, PPARD | TP53 3507/4885OPRM1 758/4885OPRD1 616/4885 |
| US-20160145204-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | SMURF2, SMURF1, ABCB4 | TP53 104/4885OPRM1 4215/4885OPRD1 3649/4885 |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | PPARA, PPARG, PPARD | TP53 3507/4885OPRM1 758/4885OPRD1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.